NCT06219018View on ClinicalTrials.gov

Effect of Honey For CIN II

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Cervical Intraepithelial Neoplasia-IIHigh Risk Human Papillomavirus
Interventions
DRUG

Medical grade honey formulation (MGH) (L-Mesitran®)

Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.

Trial Locations (2)

6149 PC

RECRUITING

Zuyderland MC, Heerlen

6229 HX

NOT_YET_RECRUITING

Maastricht University Medical Centre+, Maastricht

All Listed Sponsors
lead

Zuyderland Medisch Centrum

OTHER